Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma After Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab

Raymond Wong Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Marcos de Lima Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Daniel Couriel Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Sergio Giralt Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Chitra Hosing Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Munir Shahjahan Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Yee Chung Cheng Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Jill Bruton Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Richard Champlin Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

Issa Khouri Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA

show all

Abstract

A 31-year-old man with a diffuse large-cell lymphoma in first refractory relapse received a bone marrow transplant (BMT) from a matched unrelated donor using CAMPATH-1H, carmustine, etoposide, cytarabine and melphalan as conditioning regimen, and methotrexate and tacrolimus for graft-versus-host disease (GVHD) prophylaxis. The transplant was complicated by grade II skin acute GVHD. Lymphoma relapse occurred 4 months post-transplant. Immunosuppression withdrawal plus rituximab induced a complete response. He remains in complete remission (CR) 11 months post-immunosuppression withdrawal and 15 months post-transplant.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma After Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab

Information for

Open access

Opportunities

Help and information

Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma After Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature